These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11052223)

  • 1. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis.
    Graybiel AM; Canales JJ; Capper-Loup C
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S71-7. PubMed ID: 11052223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia.
    Wang Q; Zhang W
    Front Neural Circuits; 2016; 10():105. PubMed ID: 28066191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine dysregulation syndrome and levodopa-induced dyskinesias in Parkinson disease: common consequences of anomalous forms of neural plasticity.
    Linazasoro G
    Clin Neuropharmacol; 2009; 32(1):22-7. PubMed ID: 18978500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of the basal ganglia in Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Rodríguez M; Lanciego JL; Artieda J; Gonzalo N; Olanow CW
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S8-19. PubMed ID: 11052215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
    Samadi P; Grégoire L; Morissette M; Calon F; Hadj Tahar A; Bélanger N; Dridi M; Bédard PJ; Di Paolo T
    Neuropharmacology; 2008 Feb; 54(2):258-68. PubMed ID: 18001807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.
    Cenci MA; Ohlin KE; Rylander D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S59-63. PubMed ID: 20083009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in understanding L-DOPA-induced dyskinesia.
    Cenci MA; Lindgren HS
    Curr Opin Neurobiol; 2007 Dec; 17(6):665-71. PubMed ID: 18308560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
    Calon F; Hadj Tahar A; Blanchet PJ; Morissette M; Grondin R; Goulet M; Doucet JP; Robertson GS; Nestler E; Di Paolo T; Bédard PJ
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S92-100. PubMed ID: 11052226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Cerovic M; Bagetta V; Pendolino V; Ghiglieri V; Fasano S; Morella I; Hardingham N; Heuer A; Papale A; Marchisella F; Giampà C; Calabresi P; Picconi B; Brambilla R
    Biol Psychiatry; 2015 Jan; 77(2):106-15. PubMed ID: 24844602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Johansson PA; Andersson M; Andersson KE; Cenci MA
    Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
    Cenci MA; Lundblad M
    J Neurochem; 2006 Oct; 99(2):381-92. PubMed ID: 16942598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.
    Frucht S; Fahn S; Chin S; Dhawan V; Eidelberg D
    Mov Disord; 2000 Mar; 15(2):340-3. PubMed ID: 10752591
    [No Abstract]   [Full Text] [Related]  

  • 19. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.